Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6.41
ACRX's Cash to Debt is ranked higher than
74% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.16 vs. ACRX: 6.41 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 6.41

Equity to Asset 0.65
ACRX's Equity to Asset is ranked higher than
71% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. ACRX: 0.65 )
ACRX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.65

-0.01
0.69
F-Score: 4
Z-Score: 6.93
M-Score: 5.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -22.60
ACRX's Operating margin (%) is ranked higher than
51% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.59 vs. ACRX: -22.60 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -22.6

-1805.22
-22.6
Net-margin (%) -79.40
ACRX's Net-margin (%) is ranked lower than
53% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. ACRX: -79.40 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -79.4

-1875.09
-79.4
ROE (%) -32.02
ACRX's ROE (%) is ranked lower than
52% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. ACRX: -32.02 )
ACRX' s 10-Year ROE (%) Range
Min: -115.07   Max: -32.02
Current: -32.02

-115.07
-32.02
ROA (%) -21.29
ACRX's ROA (%) is ranked lower than
51% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.86 vs. ACRX: -21.29 )
ACRX' s 10-Year ROA (%) Range
Min: -210.01   Max: -21.29
Current: -21.29

-210.01
-21.29
ROC (Joel Greenblatt) (%) -128.73
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.89 vs. ACRX: -128.73 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1486.8   Max: -128.73
Current: -128.73

-1486.8
-128.73
EBITDA Growth (%) -68.80
ACRX's EBITDA Growth (%) is ranked lower than
54% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.90 vs. ACRX: -68.80 )
ACRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -65
Current: -68.8

EPS Growth (%) -70.00
ACRX's EPS Growth (%) is ranked lower than
53% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ACRX: -70.00 )
ACRX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -64.9
Current: -70

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ACRX Guru Trades in

Q4 2012

ACRX Guru Trades in Q4 2012

Louis Moore Bacon 150,000 sh (New)
» More
Q1 2013

ACRX Guru Trades in Q1 2013

Louis Moore Bacon Sold Out
» More
Q1 2014

ACRX Guru Trades in Q1 2014

Louis Moore Bacon 36,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ACRX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.70
ACRX's P/B is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. ACRX: 6.70 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 6.7

2.16
78
P/S 14.90
ACRX's P/S is ranked lower than
57% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.56 vs. ACRX: 14.90 )
ACRX' s 10-Year P/S Range
Min: 0   Max: 163
Current: 14.9

0
163
EV-to-EBIT 16.90
ACRX's EV-to-EBIT is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.48 vs. ACRX: 16.90 )
ACRX' s 10-Year EV-to-EBIT Range
Min: 4.2   Max: 9.4
Current: 16.9

4.2
9.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.90
ACRX's Price/Net Cash is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 7.90 )
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 25
Current: 7.9

2.2
25
Price/Net Current Asset Value 7.90
ACRX's Price/Net Current Asset Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 7.90 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 25
Current: 7.9

2.2
25
Price/Tangible Book 7.00
ACRX's Price/Tangible Book is ranked higher than
62% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.99 vs. ACRX: 7.00 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 7

2.08
57.94
Price/Median PS Value 0.30
ACRX's Price/Median PS Value is ranked lower than
52% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.31 vs. ACRX: 0.30 )
ACRX' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 3.31
Current: 0.3

0.34
3.31

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:R5X.Germany
Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Our Partners
US Stock Futures Down In Pre-Market Trade Jul 7 2014 - BENZINGA

More From Other Websites
AcelRx's Upcoming PDUFA And Trade Recommendations Jul 07 2014
AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for... Jul 07 2014
2:29 am AcelRx and Grunenthal announce submission of European Marketing Authorization Application... Jul 07 2014
AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month Jul 02 2014
AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference Jun 19 2014
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Rises 9.0% Jun 17 2014
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Jun 16 2014
Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled... Jun 03 2014
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 02 2014
AcelRx Pharmaceuticals Announces The Departure Of David Chung Jun 02 2014
AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference May 29 2014
AcelRx management to meet with Piper Jaffray May 29 2014
Nasdaq stocks posting largest percentage increases May 20 2014
AcelRx files to sell 3.07M shares of common stock for holders May 19 2014
AcelRx files $150M mixed securities shelf May 19 2014
AcelRx management to meet with Jefferies May 19 2014
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference May 19 2014
ACELRX PHARMACEUTICALS INC Financials May 16 2014
AcelRx Pharmaceuticals' (ACRX) CEO Richard King on Q1 2014 Results - Earnings Call Transcript May 08 2014
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide